Newsroom

Sorted by: Latest

-

ALSAC Names Martin Hand Chief Development Officer; Welcomes Deb Garcia as Senior Vice President of Strategy

MEMPHIS, Tenn.--(BUSINESS WIRE)--ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital®, today announced that Martin Hand has been appointed chief development officer. In his new role, Hand leads ALSAC’s revenue-generation and development efforts, including fundraising and philanthropy, corporate partnerships, donor acquisition and retention strategies, planned giving, direct response campaigns and other revenue-driving programs. ALSAC also announced that D...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 06.01.2026 LANDXEN.LN IE000C75IMX8 22,412.00 USD 419,941.58 18.737  ...
-

BANK OF NEW YORK MELLON UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 1/6/2026 Issue ¦ Standard Chartered Bank - Series No 276 USD 21,000,000 FRN due October 2028     ISIN Number ¦ XS2701599826 ISIN Reference ¦ 270159982 Issue Nomin USD ¦ 21000000 Period ¦ 10/14/2025 to 1/13/2026   Payment Date 1/13/2026 Number of Days ¦ 91 Rate ¦ 5.18878   Denomination USD ¦ 1000   ¦ 21000000   ¦       Amount Payable per Denomination ¦ 13.12   ¦ 275520   ¦       Bank of New York    ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 06.01.2026 LANDXN.LN IE000RN036E0 28,035.00 USD 572,049.49 20.405  ...
-

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads With Fostamatinib and Hutchmed's Sovleplenib Emerges as Late-Stage Breakthrough Candidate for ITP - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Global SYK Inhibitor Market Growth 2020-2024: 13% CAGR Approved SYK Inhibitor Drugs: 1 Dosage, Price & Sales Insight of Approved Drug Global Market Trend, Size & Future Opportunity Outlook Comprehensive Insight on Global SYK Inhibitors Clinical Pipeline: > 15 Drugs Global SYK Inhibitors...
-

Dr. Rasha Kelej, CEO of Merck Foundation, Named One of ‘100 Most Influential Africans 2025’ Alongside Presidents of Angola, South Africa, and Ghana by New African Magazine, UK

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Dr. Rasha Kelej, CEO of Merck Foundation, has been recognized as one of the 100 Most Influential Africans by New African Magazine (UK)....
-

Pilot's New App Update Keeps Drivers Moving

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Pilot, the largest network of travel centers, is bringing an all-new look to the Pilot app with a redesigned, faster and more intuitive experience that keeps drivers moving. The update is the next phase in building a unified and consistent brand for Pilot—at the pump, in stores and online. “Every journey is better with a wingman, and the Pilot app is built to be that trusted companion,” says Kari Irons, vice president of marketing and brand at Pilot. “Together...
-

Sopra Steria: Half Yearly Report on the Liquidity Contract with ODDO BHF SCA

PARIS--(BUSINESS WIRE)--Regulatory News: As regards the liquidity contract awarded by the company Sopra Steria Group (Paris:SOP) to ODDO BHF SCA, as of the 31st December 2025, the following means were included in the liquidity account: 12,328 shares; 5,098,339.99 euros in cash. At this time of the last half yearly statement on 30th June 2025, the following means were included in the liquidity account: 11,847 shares; 5,539,019.82 euros in cash. During the period from 01/07/2025 to 31/12/2025 the...
-

Half Year Median Technologies Liquidity Contract Statement

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2025: 37,758 shares €166,854.84 in cash. Transactions during the second half of 2025: BUY 363,473 shares 991,855.31 EUR 582 transactions SELL 386,523 shares 1,101,296.51 EUR 506 transactions For information, a...
-

Median Technologies : Bilan semestriel du contrat de liquidité

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News : Au titre du contrat de liquidité portant sur les actions de la société Median Technologies (FR0011049824, ALMDT, éligible au plan PEA/PME, “Median” ou “la Société”) confié à TP ICAP (Europe), les moyens suivants figuraient au compte de liquidité à la date du 31/12/2025 : 37 758 titres 166 854,84 Euros en espèce. Au cours du second semestre 2025, il a été négocié un total de : ACHAT 363 473 titres 991 855,31 EUR 582 transactions VENTE...